 Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation NASDAQ: INCY to distribute tafasitamab and pemigatinib Pemazyre in Latin America. Related: Incytes Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada. 